Healthcare Industry News: ELIQUIS
News Release - August 5, 2021
Breckenridge Announces Final Approval of its ANDA for Apixaban Tablets (generic for Eliquis(R))BERLIN, Conn., Aug. 5, 2021 -- (Healthcare Sales & Marketing Network) -- Breckenridge Pharmaceutical, Inc. announces today that the U.S. Food and Drug Administration has granted final approval of its Abbreviated New Drug Application for Apixaban Tablets (generic for ELIQUIS®). This product was developed by Towa Pharmaceutical Europe, S.L. in its manufacturing facility located in Martorelles, Spain. According to industry sales data, ELIQUIS generated annual sales of $14 billion during the twelve months ending May 2021. Breckenridge has been granted a license under confidential terms permitting Breckenridge to launch generic Apixaban Tablets under its Abbreviated New Drug Application at a later date.
Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients. With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve. www.bpirx.com
Source: Breckenridge Pharmaceutical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.